Sana's focus on clinical evidence

Pilot Fibromyalgia Clinical Study

Objective: The Pilot Fibromyalgia Clinical Study was a single arm 20-person trial in which patients who had failed to find adequate relief from traditional treatments were given the Sana device to use for two+ times a day for two weeks.

Measures on Pain Visual Analog Scale

Sana improved pain levels* amongst patients from very intense to distressing in 2 weeks. Sana showed a 20% reduction in pain below Best Medical Therapy Baseline P=0.002

(64.2-50.7 on VAS scale) = 20% Pvalue = 0.0020 (Most 5 severe pain patients saw a 39% decrease)



Measures of GAD-7 (Anxiety)

Sana improved anxiety levels* amongst patients from moderate to mild in two weeks. Best Medical Therapy Baseline showed 10% reductions, Sana an additional 36% = total 46% reduction. P=0.0001



Results: The participants in this study reduced their perception of pain by 20% (p=0.002) as well as reducing their ratings of anxiety by 36% (p=0.0054). In addition 84% of participants had a reduction in pain and 85% of participants chose to continue using the device after the study.

Opioid Dependency Clinical Study

Objective: The Opioid Dependence Study was a double-blind Active vs. Sham crossover trial which examined the improvement in withdrawal symptom management after the use of the Sana device versus sham.

SOWS* Means Scores by Treatment Episode

Active lower at all time points except one. SOWS reduced by 36% on average.



*The Subjective Opiate Withdrawal Scale (SOWS) is a self-administered scale for grading opioid withdrawal symptoms

VAS-A Anxiety Scores*

Anxiety scores across study period — Active lowered anxiety by 36%, rising to 45% on average at end of study period when withdrawal symptoms were most severe.

*Indicative data, measures of anxiety is an emotional state characterized by apprehension and fear resulting from anticipation of a threatening event using a Visual Analogue Scale for Anxiety

Results: These figures show that participants in this trial reduced their subjective perception of opioid withdrawal (SOWS) by 36% on average as well as their anxiety ratings 36% to 45% on average.

Recovery User Experience Study

Objective: The Recovery Study was a parallel arm double-blind comparison of Active vs. Sham on performance, fatigue, and pain measures of health adults during a 24-hour period of sleep deprivation.

Results: The chart shows that participants who received the Sana device had a statistically trending average increase in reaction time on the Psychomotor Vigilance Test (PVT) of 94ms over the sham device (p = 0.06). This results suggests that following the use of the Sana device a strong state of relaxation is experienced by participants that is demonstrated by slower reaction times.

Group with Subject Data
PTV outcome = MeansRTms



Sana device is not approved by the FDA for any medical condition. These clinical results are to support future FDA submissions.

sana
Relief made possible.

Questions? Contact our support team.
720-310-3370 | physiciansupport@sana.io | www.sana.io
Visit www.sana.io/instructions-sana-device for our Use and Video Guide.

sana
Relief made possible.

Accelerate Your Patient's Relief

Sana's goal is to provide your patients with relief, allowing for them to achieve optimal health and wellness.

Audiovisual Stimulation Technology

The Sana is a wearable neuromodulation device that delivers a patented sequence of Audiovisual Stimulation (AVS). AVS is a form of neurofeedback and a non-pharmacological intervention that affects the central nervous system by synchronizing groups of neurons to frequencies of light and sound presented to the eyes and ears of the users.



When the brain is given a stimulus through the eyes and ears it emits a responsive electrical charge, called a Cortical Evoked Response (CER). These electrical responses, measured via electrodes, travel throughout the brain and are ultimately perceived as vision and audible sound. When the brain recognizes a stimulus, it synchronizes to it, know as Frequency Following Response (FFR). The brain follows a complex series of electrical patterns every time it goes into healthy relaxation. FFR can be used to trigger each of those electrical patterns, in turn, to put the brain into a restful, healthy state of relaxation.

A 16 minute session that accelerates mental and physical recovery.



EEG of patient with severe pain causing less sleep and more stress

EEG after using Sana for four hours (cumulative use) seeing better sleep, less stress and being more calm

Sana leverages these electrical patterns that resemble the effect of long term meditative practices by encouraging the brain to synchronize and balance the energy across hemispheres, leading to a restful state of mind.

Sana is revolutionizing the way your patients can achieve relief

Sana's Key Features:

- Non-addictive, non-narcotic
- Portable and easy to use — simple mask and headphones
- Delivers very gentle coordinated pulses of light through closed eyelids and sound through any commercially available headphones
- A Sana session lasts 16 minutes, with many experiencing rapid sleep onset
- No risks associated with stopping a session early, if needed

Proven Benefits:

- Clearing a busy mind
- Supporting enhanced rest and relaxation
- Improving sleep management
- Reducing feelings of stress
- Enhancing recovery from fatigue

Sana App

Patients use the Sana App to track their overall wellness and sleep insights with each use of the Sana. A dashboard is provided to help evaluate overall trends in sleep, pain and mood.

Daily use of the Sana is recommended for maximum benefits and the Sana App helps review their consistency in use of the Sana. Help your patients achieve relief and live with optimal health.

The Sana is in clinical trials for a number of clinical applications but is not yet FDA approved for any specific indication. The FDA considers the Sana to be of non-significant risk, and no known serious adverse events or contraindications against use in combination with other drugs or therapies are known. However, the following patients should not use the Sana:

- Persons under the age of 18
- Pregnant women
- History or presence of photo-sensitive epilepsy or other photo-sensitive conditions
- History or presence of condition(s) that may affect balance, such as seizure disorders, tinnitus or vertigo
- Visually or hearing impaired, including those with a significant difference in hearing between ears or sight between eyes
- Presence of inflammation or broken skin around the eyes